Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes x No ¨

As of October 27, 2014, there were 34,211,282 of the Registrant’s common shares, no par value, issued and outstanding.

	September 26,			December 31,
	2014			2013
ASSETS
Current Assets
Cash and cash equivalents	$	53,549		$	60,980
Accounts receivable, net of allowance of $435 and $575, respectively		56,673			48,552
Inventories		62,815			58,290
Income taxes receivable		5,251			5,715
Deferred tax assets		8,699			6,351
Prepaid expenses and other current assets		4,392			5,134
Assets of discontinued operations		631			16,088
Total current assets		192,010			201,110
Property, plant and equipment, net		39,634			31,303
Deferred tax assets		438			519
Other assets		14,131			9,426
Intangible assets, net		93,543			65,293
Goodwill		110,783			71,156
Total assets	$	450,539		$	378,807
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Current portion of long-term debt	$	7,500		$	7,500
Accounts payable		31,223			24,361
Income taxes payable		2,305			1,018
Deferred tax liabilities		172			214
Accrued expenses and other current liabilities		19,078			22,288
Liabilities of discontinued operations		1,437			6,398
Total current liabilities		61,715			61,779
Long-term debt		114,375			64,000
Deferred tax liabilities		4,636			—
Income taxes payable		7,484			5,596
Other liabilities		13,551			5,029
Total liabilities		201,761			136,404
Commitments and Contingencies (Note 13)
Stockholders’ Equity:
Common shares, no par value; Authorized shares: unlimited; Issued and outstanding: 34,209 and 33,991, respectively		423,856			423,856
Additional paid-in capital		27,968			25,383
Accumulated deficit		(194,680	)		(200,913	)
Accumulated other comprehensive loss		(8,795	)		(6,342	)
Total GSI Group Inc. stockholders’ equity		248,349			241,984
Noncontrolling interest		429			419
Total stockholders’ equity		248,778			242,403
Total liabilities and stockholders’ equity	$	450,539		$	378,807

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months Ended						Nine Months Ended
	September 26,			September 27,			September 26,			September 27,
	2014			2013			2014			2013
Sales	$	94,656		$	79,858		$	270,694		$	234,698
Cost of sales		54,973			45,697			160,255			136,667
Gross profit		39,683			34,161			110,439			98,031
Operating expenses:
Research and development and engineering		7,735			6,031			21,117			17,962
Selling, general and administrative		21,512			19,006			62,540			57,069
Amortization of purchased intangible assets		2,843			1,772			7,463			5,625
Restructuring and acquisition related costs		771			1,553			1,949			4,724
Total operating expenses		32,861			28,362			93,069			85,380
Operating income from continuing operations		6,822			5,799			17,370			12,651
Interest income (expense), net		(1,453	)		(841	)		(3,665	)		(2,660	)
Foreign exchange transaction gains (losses), net		1,030			(1,723	)		950			(963	)
Other income (expense), net		733			542			1,733			1,204
Income from continuing operations before income taxes		7,132			3,777			16,388			10,232
Income tax provision		2,013			1,533			5,007			4,954
Income from continuing operations		5,119			2,244			11,381			5,278
Loss from discontinued operations, net of tax		(273	)		(185	)		(4,817	)		(1,643	)
Loss on disposal of discontinued operations, net of tax		(321	)		(281	)		(321	)		(592	)
Consolidated net income		4,525			1,778			6,243			3,043
Less: Net income (loss) attributable to noncontrolling interest		—			12			(10	)		(42	)
Net income attributable to GSI Group Inc.	$	4,525		$	1,790		$	6,233		$	3,001

Earnings per common share from continuing operations:
Basic	$	0.15		$	0.07		$	0.33		$	0.15
Diluted	$	0.15		$	0.07		$	0.33		$	0.15
Loss per common share from discontinued operations:
Basic	$	(0.02	)	$	(0.02	)	$	(0.15	)	$	(0.07	)
Diluted	$	(0.02	)	$	(0.02	)	$	(0.15	)	$	(0.07	)
Earnings per common share attributable to GSI Group Inc.:
Basic	$	0.13		$	0.05		$	0.18		$	0.08
Diluted	$	0.13		$	0.05		$	0.18		$	0.08

Weighted average common shares outstanding—basic		34,389			34,102			34,333			34,058
Weighted average common shares outstanding—diluted		34,793			34,417			34,725			34,325

The accompanying notes are an integral part of these consolidated financial statements.

	Three Months Ended						Nine Months Ended
	September 26,			September 27,			September 26,			September 27,
	2014			2013			2014			2013
Consolidated net income	$	4,525		$	1,778		$	6,243		$	3,043
Other comprehensive income (loss):
Foreign currency translation adjustments, net of tax (1)		(3,845	)		3,764			(2,902	)		(2,016	)
Pension liability adjustments, net of tax (2)		435			(370	)		449			802
Total other comprehensive income (loss)		(3,410	)		3,394			(2,453	)		(1,214	)
Total consolidated comprehensive income		1,115			5,172			3,790			1,829
Less: Comprehensive (income) loss attributable to noncontrolling interest		—			12			(10	)		(42	)
Comprehensive income attributable to GSI Group Inc.	$	1,115		$	5,184		$	3,780		$	1,787

The accompanying notes are an integral part of these consolidated financial statements.

	Nine Months Ended
	September 26,			September 27,
	2014			2013
Cash flows from operating activities:
Consolidated net income	$	6,243		$	3,043
Less: Loss from discontinued operations, net of tax		5,138			2,235
Income from continuing operations		11,381			5,278
Adjustments to reconcile income from continuing operations to net cash provided by operating activities of continuing operations:
Depreciation and amortization		17,495			14,792
Provision for inventory excess and obsolescence		704			1,407
Share-based compensation		3,412			4,170
Deferred income taxes		(1,653	)		2,166
Earnings from equity investment		(1,707	)		(1,181	)
Non-cash interest expense		982			735
Non-cash restructuring and acquisition related charges		944			19
Other non-cash items		496			1,059
Changes in assets and liabilities which (used) provided cash, excluding effects from businesses purchased or classified as held for sale:
Accounts receivable		(835	)		(6,330	)
Inventories		116			(636	)
Prepaid expenses, income taxes receivable and other current assets		911			13,955
Accounts payable, accrued expenses, income taxes payable and other current liabilities		1,706			5,244
Other non-current assets and liabilities		463			645
Cash provided by operating activities of continuing operations		34,415			41,323
Cash used in operating activities of discontinued operations		(761	)		(6,875	)
Cash provided by operating activities		33,654			34,448
Cash flows from investing activities:
Purchases of property, plant and equipment		(3,783	)		(2,962	)
Acquisition of businesses, net of cash acquired and escrow recovery		(88,238	)		(82,653	)
Proceeds from the sale of property, plant and equipment		57			255
Cash used in investing activities of continuing operations		(91,964	)		(85,360	)
Cash provided by investing activities of discontinued operations		4,344			12,439
Cash used in investing activities		(87,620	)		(72,921	)
Cash flows from financing activities:
Borrowings under revolving credit facility		77,000			60,000
Repayments of long-term debt and revolving credit facility		(26,625	)		(31,625	)
Payments for debt issuance costs		(712	)		(145	)
Payments of withholding taxes from stock-based awards		(1,605	)		(820	)
Capital lease payments		(938	)		(608	)
Excess tax benefits from stock-based awards		210			—
Other financing activities		261			—
Cash provided by financing activities of continuing operations		47,591			26,802
Cash provided by financing activities of discontinued operations		—			—
Cash provided by financing activities		47,591			26,802
Effect of exchange rates on cash and cash equivalents		(1,056	)		(427	)
Decrease in cash and cash equivalents		(7,431	)		(12,098	)
Cash and cash equivalents, beginning of period		60,980			65,788
Cash and cash equivalents, end of period	$	53,549		$	53,690
Supplemental disclosure of cash flow information:
Cash paid for interest	$	2,644		$	1,674
Cash paid for income taxes	$	3,944		$	1,935
Income tax refunds received	$	150		$	12,607

Supplemental disclosure of non-cash financing activity:
Assets acquired under capital lease obligations	$	9,133		$	-

The accompanying notes are an integral part of these consolidated financial statements.

GSI Group Inc. and its subsidiaries (collectively referred to as the “Company”) design, develop, manufacture and sell precision photonic and motion control components and subsystems to Original Equipment Manufacturers (OEM’s) in the medical equipment and advanced industrial technology markets. Our highly engineered enabling technologies include laser sources, laser scanning and beam delivery products, optical data collection and machine vision technologies, medical visualization and informatics solutions and precision motion control products. We specialize in collaborating with OEM customers to adapt our component and subsystem technologies to deliver highly differentiated performance in their applications.

The accompanying unaudited interim consolidated financial statements have been prepared in U.S. dollars and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”), the instructions to Form 10-Q and the provisions of Regulation S-X pertaining to interim financial statements. Accordingly, certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The interim consolidated financial statements and notes included in this report should be read in conjunction with the financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. In the opinion of management, these interim consolidated financial statements include all adjustments and accruals of a normal and recurring nature necessary for a fair presentation of the results of the interim periods presented. The results for interim periods are not necessarily indicative of results to be expected for the full year or for any future periods.

The interim consolidated financial statements include the accounts of the Company and its 50% owned joint venture, Excel Laser Technology Private Limited (the “India JV”), which is reported as discontinued operations in the Company’s consolidated statements of operations. Intercompany transactions and balances have been eliminated. During the second quarter of 2013, the Company’s ownership percentage in a privately held company located in the United Kingdom, Laser Quantum Ltd. (“Laser Quantum”), increased from approximately 25% to 41% as a result of a share buy-back program by Laser Quantum. The Company continues to record the results of this entity under the equity method as it does not have a controlling interest in the entity.

The Company’s unaudited interim financial statements are prepared on a quarterly basis ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of sales and expenses during the reporting periods. The Company evaluates its estimates based on historical experience, current conditions and various other assumptions that it believes are reasonable under the circumstances. Estimates and assumptions are reviewed on an on-going basis and the effects of revisions are reflected in the period in which they are deemed to be necessary. Actual results could differ significantly from those estimates.

Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern

In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (“ASU”) 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)," which requires management to assess a company’s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. ASU 2014-15 will be effective for annual reporting periods ending after December 15, 2016. Early application is permitted. The Company does not expect the adoption of ASU 2014-15 to have an impact on the Company’s financial statements.

In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers”, which provides guidance for revenue recognition. ASU 2014-09 supersedes the revenue recognition requirements in Accounting Standards Codification (“ASC”) 605, “Revenue Recognition,” and requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 will be effective for annual and interim reporting periods beginning after December 15, 2016. Early adoption is not permitted. Upon adoption, an entity may apply the new guidance either retrospectively to each prior reporting period presented or retrospectively only to customer contracts not yet completed as of the date of adoption with the cumulative effect of initially applying the standard recognized in beginning retained earnings at the date of the initial application. The Company is currently evaluating the impact of the new standard on the Company’s financial statements.

Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity

In April 2014, the FASB issued ASU 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity.” ASU 2014-08 provides guidance on determining when disposals can be presented as discontinued operations. ASU 2014-08 requires that only disposals representing a strategic shift that has (or will have) a major effect on an entity’s operations and financial results should be presented as discontinued operations. A strategic shift may include a disposal of a major line of business, a major equity method investment or a major part of an entity. Additionally, ASU 2014-08 requires expanded disclosures regarding discontinued operations. ASU 2014-08 will be effective prospectively for reporting periods beginning after December 15, 2014, with early adoption permitted. The Company will adopt this pronouncement in January 2015. The adoption of this amendment is not expected to have a material impact on the Company’s consolidated financial statements.

On July 15, 2014, the Company completed the sale of certain assets and liabilities of its Scientific Lasers business operating under the Continuum brand name for approximately $6.5 million in cash, net of working capital adjustments. In accordance with the purchase and sale agreement, $1.5 million of the sales proceeds is held in escrow until January 2016. The Company has recorded the $1.5 million escrow in other long term assets on the balance sheet.

In 2013, the Company consummated the sale of certain assets and liabilities of the Semiconductor Systems business for $8.6 million in cash, net of working capital adjustments.

The major components of the assets and liabilities of discontinued operations as of September 26, 2014 and December 31, 2013, respectively, are as follows (in thousands):

Assets and liabilities of discontinued operations as of September 26, 2014 include the balances of the India JV. In addition, liabilities of discontinued operations as of September 26, 2014 include a $0.6 million working capital settlement that is due to the buyers of the Scientific Lasers business.

The following table presents the operating results which are reported as discontinued operations in the Company’s consolidated statements of operations (in thousands):

The loss from discontinued operations during the three months ended September 26, 2014 includes a $0.5 million fair value write-down of the India JV. The Company is currently in negotiations with the joint venture partner to dissolve the joint venture. The loss from discontinued operations during the nine months ended September 26, 2014 includes a $3.0 million fair value write-down of the Scientific Lasers business to its fair value less costs to sell and the $0.5 million fair value write-down of the India JV.

On March 14, 2014, the Company completed the acquisition of JADAK LLC, JADAK Technologies, Inc. and Advanced Data Capture Corporation (together, “JADAK”), a North Syracuse, New York-based provider of optical data collection and machine vision technologies to OEM medical device manufacturers, for $93.7 million in cash, net of working capital adjustments. The Company expects that the addition of JADAK will enable the Company to offer a broader range of highly engineered enabling technologies to leading medical equipment manufacturers. Acquisition-related costs are included in restructuring and acquisition related costs in the consolidated statements of operations. Acquisition related costs are as follows (in thousands):

The acquisition of JADAK has been accounted for as a business combination. The allocation of the purchase price is based upon a valuation of assets and liabilities acquired. Assets acquired and liabilities assumed have been recorded at their estimated fair values as of the acquisition date. The fair values of intangible assets were based on valuations using an income approach, with estimates and assumptions provided by management of JADAK and the Company. The excess of the purchase price over the tangible assets, identifiable intangible assets and assumed liabilities was recorded as goodwill. The Company’s estimates and assumptions in determining the estimated fair values of certain assets and liabilities are subject to change within the measurement period (up to one year from the acquisition date) as a result of additional information obtained with regards to facts and circumstances that existed as of the acquisition date. The purchase price allocation is preliminary and the primary areas of the purchase price allocation that are not yet finalized relate to income taxes and the amount of residual goodwill.

Based upon a preliminary valuation, the total purchase price was allocated as follows (in thousands):

During the third quarter of 2014, the Company made adjustments to the preliminary purchase price allocation primarily related to the inventory valuation and an adjustment to other liabilities, resulting in an increase in goodwill of $0.6 million.

The fair value of intangible assets is comprised of the following (dollar amounts in thousands):

The purchase price allocation resulted in $45.0 million of goodwill and $40.3 million of identifiable intangible assets, $63.1 million of which is expected to be deductible for tax purposes. Intangible assets are being amortized over their weighted average useful lives primarily based upon the pattern in which anticipated economic benefits from such assets are expected to be realized. The goodwill recorded represents the anticipated incremental value of future cash flow potential attributable to: (i) JADAK’s ability to develop and market new products and technologies, (ii) JADAK’s ability to develop relationships with new customers, and (iii) expected sales synergies from cross-selling current and future product offerings of both JADAK and the Company to OEM customers.

The operating results of JADAK have been included in our consolidated statement of operations since the acquisition date. JADAK has contributed sales of $14.9 million and $32.6 million for the three and nine months ended September 26, 2014, respectively, and operating income from continuing operations of $1.2 million and $2.3 million for the three and nine months ended September 26, 2014, respectively. The pro forma information for all periods presented below includes the effects of business combination accounting resulting from the acquisition of JADAK, including amortization charges from acquired intangible assets, interest expense on borrowings in connection with the acquisition, earn-out expenses, and the related tax effects as though the acquisition had been consummated at the beginning of 2013. These pro forma results exclude the impact of transaction costs and the related tax effects included in the historical results. The pro forma financial information is presented for comparative information

purposes only and is not necessarily indicative of the results of operations that would have been achieved if the acquisition had actually taken place at the beginning of 2013.

Changes in accumulated other comprehensive income (loss) is as follows (in thousands):

Basic earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding during the period. For diluted earnings per common share, the denominator also includes the dilutive effect of outstanding restricted stock units determined using the treasury stock method. For periods in which net losses are generated, the dilutive potential common shares are excluded from the calculation of diluted earnings per share as the effect would be anti-dilutive. Dilutive effects of contingently issuable shares are included in the weighted average dilutive share calculation when the contingencies have been resolved.

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):

	Three Months Ended						Nine Months Ended
	September 26,			September 27,			September 26,			September 27,
	2014			2013			2014			2013
Numerators:
Income from continuing operations	$	5,119		$	2,244		$	11,381		$	5,278
Consolidated loss from discontinued operations		(594	)		(466	)		(5,138	)		(2,235	)
Less: income (loss) attributable to noncontrolling interest		—			12			(10	)		(42	)
Loss from discontinued operations attributable to GSI Group Inc.		(594	)		(454	)		(5,148	)		(2,277	)
Net income attributable to GSI Group Inc.	$	4,525		$	1,790		$	6,233		$	3,001

Denominators:
Weighted average common shares outstanding— basic		34,389			34,102			34,333			34,058
Dilutive potential common shares		404			315			392			267
Weighted average common shares outstanding— diluted		34,793			34,417			34,725			34,325
Antidilutive common shares excluded from above		—			37			29			327

Basic Earnings (Loss) per Common Share:
From continuing operations	$	0.15		$	0.07		$	0.33		$	0.15
From discontinued operations	$	(0.02	)	$	(0.02	)	$	(0.15	)	$	(0.07	)
Basic earnings per share attributable to GSI Group Inc.	$	0.13		$	0.05		$	0.18		$	0.08

Diluted Earnings (Loss) per Common Share:
From continuing operations	$	0.15		$	0.07		$	0.33		$	0.15
From discontinued operations	$	(0.02	)	$	(0.02	)	$	(0.15	)	$	(0.07	)
Diluted earnings per share attributable to GSI Group Inc.	$	0.13		$	0.05		$	0.18		$	0.08

In October 2013, the Company’s Board of Directors authorized a share repurchase plan under which the Company may repurchase outstanding shares of the Company’s common stock up to an aggregate amount of $10.0 million. The shares may be repurchased from time to time, at the Company’s discretion, based on ongoing assessment of the capital needs of the business, the market price of the Company’s common stock, and general market conditions. Shares may also be repurchased through an accelerated stock purchase agreement, on the open market or in privately negotiated transactions in accordance with applicable federal securities laws. Repurchases may be made under certain SEC regulations, which would permit common stock to be purchased when the Company would otherwise be prohibited from doing so under insider trading laws. The share repurchase plan does not obligate the Company to acquire any particular amount of common stock. No time limit was set for the completion of the share repurchase program, and the program may be suspended or discontinued at any time. As of December 31, 2013, the Company cumulatively repurchased 50 thousand shares of its common stock in the open market for a weighted average share price of $10.49 per share. There were no share repurchases during the nine months ended September 26, 2014.

ASC 820, “Fair Value Measurements,” establishes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the third is considered unobservable:

The Company’s cash equivalents are investments in money market accounts, which represent the only asset the Company measures at fair value on a recurring basis. The Company determines the fair value of our cash equivalents using a market approach based on quoted prices in active markets. The fair values of cash, accounts receivable, income taxes receivable, accounts payable, income taxes payable, accrued expenses and other current liabilities approximate their carrying values because of their short-term nature.

The following table summarizes the fair values of our financial assets as of September 26, 2014 (in thousands):

The following table summarizes the fair values of our financial assets as of December 31, 2013 (in thousands):

See Note 9 to Consolidated Financial Statements for discussion of the estimated fair value of the Company’s outstanding debt.

Goodwill is recorded when the consideration for a business combination exceeds the fair value of net tangible and identifiable intangible assets acquired. The Company tests its goodwill balances annually for impairment as of the beginning of the second quarter or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. The Company performed its annual goodwill impairment test at the beginning of the second quarter of 2014 and noted no impairment of goodwill.

On September 24, 2014, we received a payment of $5.4 million, the full remaining amount held in an escrow account established upon the closing of the acquisition of NDS Surgical Imaging, LLC (“NDS”) in January 2013. The escrow recovery resulted from the Company’s claims for a breach of certain terms of the January 15, 2013 Securities Purchase Agreement for the acquisition of NDS. The escrow recovery was accounted for as a reduction to goodwill as the $5.4 million payment was clearly and directly related to the acquisition price. The following table summarizes changes in goodwill for the nine months ended September 26, 2014 (in thousands):

Goodwill acquired from the JADAK acquisition and the recovery of escrow from the NDS acquisition is reflected in the Medical Technologies segment. Goodwill by reportable segment as of September 26, 2014 is as follows (in thousands):

Goodwill by reportable segment as of December 31, 2013 is as follows (in thousands):

Intangible assets as of September 26, 2014 and December 31, 2013, respectively, are summarized as follows (in thousands):

	September 26, 2014							December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Amortizable intangible assets:
Patents and acquired technologies	$	79,279	$	(60,726	)	$	18,553	$	68,500	$	(56,327	)	$	12,173
Customer relationships		79,112		(29,716	)		49,396		55,585		(24,340	)		31,245
Customer backlog		3,078		(2,391	)		687		1,269		(1,269	)		—
Non-compete covenant		1,830		(250	)		1,580		—	—				—
Trademarks and trade names		15,478		(5,178	)		10,300		13,378		(4,530	)		8,848
Amortizable intangible assets		178,777		(98,261	)		80,516		138,732		(86,466	)		52,266
Non-amortizable intangible assets:
Trade names		13,027		—			13,027		13,027		—			13,027
Totals	$	191,804	$	(98,261	)	$	93,543	$	151,759	$	(86,466	)	$	65,293

All definite-lived intangible assets are amortized either on a straight-line basis or an economic benefit basis over their remaining useful life. Amortization expense for customer relationships, customer backlog, non-compete covenant, definite-lived trademarks, trade names and other intangibles is included in operating expenses in the accompanying consolidated statements of operations. Amortization expense for patents and acquired technologies is included in cost of goods sold in the accompanying consolidated statements of operations. Amortization expense is as follows (in thousands):

Estimated amortization expense for each of the five succeeding years and thereafter as of September 26, 2014 is as follows (in thousands):

The following tables provide the details of selected balance sheet items as of the periods indicated (in thousands):

The Company’s amended and restated senior secured credit agreement (the “Amended and Restated Credit Agreement”) provides for a $50.0 million, 5-year, term loan facility due in quarterly installments of $1.9 million beginning in January 2013 and a $75.0 million, 5-year, revolving credit facility (collectively, the “Senior Credit Facilities”) that matures in December 2017. Quarterly installments due in the next twelve months amount to $7.5 million and are classified as a current liability in the consolidated balance sheet. On February 10, 2014, the Company entered into a fourth amendment to the Amended and Restated Credit Agreement (the “Fourth Amendment”). The Fourth Amendment increases the revolving credit facility commitment under the Amended and Restated Credit Agreement by $100 million from $75 million to $175 million and resets the accordion feature to $100 million for future expansion.

The Company is required to satisfy certain financial and non-financial covenants under the Amended and Restated Credit Agreement. The Company is in compliance with these covenants as of September 26, 2014.

As of September 26, 2014 and December 31, 2013, the outstanding balance of the Company’s debt approximated its fair value based on current rates available to the Company for debt of the same maturity.

The table below summarizes activities relating to restricted stock units issued and outstanding under the 2010 Incentive Award Plan during the nine months ended September 26, 2014:

The total fair value of restricted stock units that vested during the nine months ended September 26, 2014 was $4.3 million based on the market price of the underlying stock on the day of vesting.

The table below summarizes share-based compensation expense recorded in income from continuing operations in the consolidated statements of operations (in thousands):

The expense recorded during each of the nine months ended September 26, 2014 and September 27, 2013 includes $0.5 million related to deferred stock units granted to the members of the Company’s Board of Directors, pursuant to the Company’s 2010 Incentive Award Plan. The expense associated with the respective deferred stock units was recognized in full on the date of grant, as the deferred stock units were fully vested and non-forfeitable upon grant.

In connection with the JADAK acquisition on March 14, 2014, the Company acquired 100% of the outstanding stock of JADAK. In addition to the total purchase price, the Company granted restricted stock units in an aggregate of 180,000 shares to the four former owner-managers of JADAK as employment inducement awards. These restricted stock units are performance based awards and will vest after two years if certain financial targets have been achieved.

On May 15, 2014, the Company’s shareholders approved the amendment and restatement of the 2010 Incentive Award Plan. The Amended and Restated Incentive Award Plan increases the amount of shares authorized for issuance under the plan from 2,898,613 shares to 4,398,613 shares, extends the term of the plan through April 9, 2024, allows the Company to continue to grant awards intended to constitute “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, and includes certain provisions that reflect good corporate governance practices.

The Company determines its estimated annual effective tax rate at the end of each interim period based on facts known at that time. The estimated annual effective tax rate is applied to the year-to-date pre-tax income at the end of each interim period. The tax effect of significant unusual items is reflected in the period in which they occur. Since the Company is incorporated in Canada, it is required to use Canada’s statutory tax rate of 27.0% in the determination of the estimated annual effective tax rate.

The Company’s effective tax rate on income from continuing operations of 28.2% and 30.6% for the three and nine months ended September 26, 2014, respectively, differ from the Canadian statutory rate of 27.0% primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, and the impact of discrete items for the period. The Company’s effective tax rate on income from continuing operations of 40.6% and 48.4% for the three and nine months ended September 27, 2013, respectively, differ from the Canadian statutory rate primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, and the impact of discrete items for the period.

The Company maintains a valuation allowance on some of its deferred tax assets in certain jurisdictions. A valuation allowance is required when, based upon an assessment of various factors, including recent operating loss history, anticipated future earnings, and prudent and reasonable tax planning strategies, it is more likely than not that some portion of the deferred tax assets will not be realized.

In conjunction with the Company’s ongoing review of its actual results and anticipated future earnings, the Company continuously reassesses the possibility of releasing the remaining valuation allowance currently in place on its deferred tax assets. A release would be reported as a reduction to income tax expense without any impact on cash flows in the quarter in which it is released.

On September 13, 2013, the IRS released final tangible property regulations under Sections 162(a) and 263(a) of the Internal Revenue Code of 1986 (the “Code”), regarding the deduction and capitalization of expenditures related to tangible property. In

addition, the IRS proposed regulations under Section 168 of the Code regarding dispositions of tangible property. These final and proposed regulations will be effective for the Company’s fiscal year ending December 31, 2014. The Company is in the process of reviewing the regulations and the related impact on its consolidated financial statements.

The following table summarizes restructuring and acquisition related expenses in the accompanying consolidated statements of operations (in thousands):

	Three Months Ended					Nine Months Ended
	September 26, 2014		September 27, 2013			September 26, 2014			September 27, 2013
2011 restructuring	$	233	$	(2	)	$	139		$	1,320
2013 restructuring		—		1,449			(66	)		2,205
Germany restructuring		—		—			—			7
Total restructuring charges	$	233	$	1,447		$	73		$	3,532
Acquisition charges	$	26	$	106		$	774		$	1,192
JADAK earn-out costs		512		—			1,102			—
Total acquisition related charges	$	538	$	106		$	1,876		$	1,192
Total restructuring and acquisition related costs	$	771	$	1,553		$	1,949		$	4,724

In November 2011, the Company announced a strategic initiative (“2011 restructuring”), which aimed to consolidate operations to reduce our cost structure and improve operational efficiency. As part of this initiative, the Company eliminated facilities through consolidation of certain manufacturing, sales and distribution facilities and exit of Semiconductor and Laser Systems businesses. The Company substantially completed the 2011 restructuring program by the end of 2013. During the three and nine months ended September 26, 2014, the Company recorded restructuring costs from facilities exited as part of our 2011 restructuring program. The restructuring costs during the three months ended September 26, 2014 increased as a result of the Company’s tenant exiting the Orlando, Florida facility, which the Company owns. The Company recorded $0.1 million and $0.4 million in depreciation expense for the Orlando, Florida facility during the three and nine months ended September 26, 2014, respectively.

The following table summarizes the accrual activities, by component, related to the Company’s restructuring plans recorded in the accompanying consolidated balance sheets (in thousands):

In accordance with the guidance in ASC 420, “Exit or Disposal Cost Obligations,” the Company records lease termination accruals based on market estimates, including the time period for which facilities will remain vacant, sublease terms, sublease rates and discount rates. The Company reviews prior estimates and current market data available to determine the appropriate value of these liabilities at period end.

The Company leases certain equipment and facilities under operating and capital lease agreements. Excluding the outstanding lease commitment assumed by the buyer of the Scientific Lasers business and the leases acquired as part of the JADAK acquisition, there have been no material changes to the Company’s leases from those discussed in Note 16 to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. The Scientific Lasers facility lease commitment as of the disposal date was $3.0 million which was assigned to the buyer. In May 2014, JADAK moved into a new facility which was recorded as a capital lease. The current and long-term portions of the capital lease have been included in accrued expenses and other current liabilities and other long-term liabilities, respectively. Future minimum lease payments under the operating and capital leases for JADAK are as follows (in thousands):

Excluding JADAK’s purchase commitments, there have been no material changes to the Company’s purchase commitments from those discussed in Note 16 to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. As of September 26, 2014, JADAK had unconditional commitments primarily for inventory purchases of $5.1 million. These purchase commitments are expected to be incurred as follows: $3.3 million in the remainder of 2014, and $1.8 million in 2015.

The Company is subject to various legal proceedings and claims that arise in the ordinary course of business. The Company does not believe that the outcome of these claims will have a material adverse effect upon its financial condition or results of operations but there can be no assurance that any such claims, or any similar claims, would not have a material adverse effect upon its financial condition or results of operations.

In the normal course of its operations, the Company executes agreements that provide for indemnification and guarantees to counterparties in transactions such as business dispositions, sale of assets, sale of products and operating leases. Additionally, the by-laws of the Company require it to indemnify certain current or former directors, officers, and employees of the Company against expenses incurred by them in connection with each proceeding in which he or she is involved as a result of serving or having served in certain capacities. Indemnification is not available with respect to a proceeding as to which it has been adjudicated that the person did not act in good faith in the reasonable belief that the action was in the best interests of the Company. Certain of our officers and directors are also a party to an indemnification agreement with the Company. These indemnification agreements provide, among other things, that the director and officer shall be indemnified to the fullest extent permitted by applicable law against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such officer or director in connection with any proceeding by reason of his or her relationship with the Company. In addition, the indemnification agreements provide for the advancement of expenses incurred by such director or officer in connection with any proceeding covered by the indemnification agreement, subject to the conditions set forth therein and to the extent such advancement is not prohibited by law. The indemnification agreements also set out the procedures for determining entitlement to indemnification, the requirements relating to notice and defense of claims for which indemnification is sought, the procedures for enforcement of indemnification rights, the limitations on and

exclusions from indemnification, and the minimum levels of directors’ and officers’ liability insurance to be maintained by the Company.

The Company evaluates the performance of, and allocates resources to, its segments based on sales, gross profit and operating profit. The Company’s reportable segments have been identified based on commonality of end markets, customers, applications and technologies amongst the Company’s individual product lines, which is consistent with the Company’s operating structure.

We operate in three reportable segments: Laser Products, Medical Technologies, and Precision Motion. The reportable segments and their principal activities consist of the following:

Our Laser Products segment designs, manufactures and markets photonics-based solutions to customers worldwide. The segment serves highly demanding photonics-based applications such as industrial material processing, and medical and life science imaging and laser procedures. The vast majority of the segment’s product offerings are sold to OEM customers. The business sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Our Medical Technologies segment designs, manufactures and markets a range of medical grade technologies, including visualization solutions, imaging informatics products, optical data collection and machine vision technologies, thermal printers, and light and color measurement instrumentation to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Our Precision Motion segment designs, manufactures and markets optical encoders, air bearing spindles and precision machined components to customers worldwide. The vast majority of the segment’s product offerings are sold into the electronics, industrial and, to a lesser extent, the medical markets. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Sales, gross profit, gross profit margin, operating income from continuing operations, and depreciation and amortization by reportable segments are as follows (in thousands):

	Three Months Ended						Nine Months Ended
	September 26, 2014			September 27, 2013			September 26, 2014			September 27, 2013
Gross Profit
Laser Products	$	20,269		$	19,252		$	54,437		$	51,436
Medical Technologies		12,945			7,535			35,672			25,271
Precision Motion		6,776			7,429			21,141			21,487
Corporate, Shared Services and Unallocated		(307	)		(55	)		(811	)		(163	)
Total	$	39,683		$	34,161		$	110,439		$	98,031

	Three Months Ended						Nine Months Ended
	September 26, 2014			September 27, 2013			September 26, 2014			September 27, 2013
Operating Income from Continuing Operations
Laser Products	$	9,857		$	7,734		$	23,828		$	17,868
Medical Technologies		(1,115	)		(469	)		(1,194	)		1,375
Precision Motion		2,796			3,223			9,525			9,657
Corporate, Shared Services and Unallocated		(4,716	)		(4,689	)		(14,789	)		(16,249	)
Total	$	6,822		$	5,799		$	17,370		$	12,651

	Three Months Ended				Nine Months Ended
	September 26, 2014		September 27, 2013		September 26, 2014		September 27, 2013
Depreciation and Amortization
Laser Products	$	1,618	$	1,701	$	4,838	$	4,735
Medical Technologies		3,745		2,143		9,552		6,762
Precision Motion		444		486		1,451		1,471
Corporate, Shared Services and Unallocated		537		455		1,654		1,824
Total	$	6,344	$	4,785	$	17,495	$	14,792

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the Consolidated Financial Statements and Notes included in Item 1 of this Quarterly Report on Form 10-Q. The MD&A contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. These forward-looking statements include, but are not limited to, expected loss from the sale of the Scientific Lasers business; anticipated financial performance; expected liquidity and capitalization; drivers of revenue growth; management’s plans and objectives for future operations, expenditures and product development and investments in research and development; business prospects; potential of future product releases; anticipated sales performance; changes in accounting principles and changes in actual or assumed tax liabilities; expectations regarding tax exposure; anticipated reinvestment of future earnings; anticipated benefits from prior acquisitions; anticipated outcomes of legal proceedings and litigation matters; efforts to reduce working capital needs; and anticipated use of currency hedges. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses and level of business activity; our significant dependence upon our customers’ capital expenditures, which are subject to cyclical market fluctuations; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our information technology systems; changes in interest rates, credit ratings or foreign currency exchange rates; risk associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; our failure to comply with local import and export regulations in the jurisdictions in which we operate; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to make divestitures that provide business benefits; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components and other goods from our suppliers; production difficulties and product delivery delays or disruptions; our compliance, or our failure to comply, with various federal, state and foreign regulations; changes in governmental regulation of our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; our ability to utilize our net operating loss carryforwards and other tax attributes; changes in tax laws, and fluctuations in our effective tax rates; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; volatility in the market price for our common shares; our ability to access cash and other assets of our subsidiaries; the influence of certain significant shareholders over our business; provisions of our articles of incorporation may delay or prevent a change in control; our significant existing indebtedness may limit our ability to engage in certain activities; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 under the heading “Risk Factors.” In this Quarterly Report on Form 10-Q, the words “anticipates,” “believes,” “expects,” “intends,” “future,” “could,” “estimates,” “plans,” “would,” “should,” “potential,” “continues,” and similar words or expressions (as well as other words or expressions referencing future events, conditions or circumstances) identify forward-looking statements. Readers should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Management and the Company disclaim any obligation to publicly update or revise any such statement to reflect any change in its expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

GSI Group Inc. and its subsidiaries (collectively referred to as the “Company”, “we”, “us”, “our”) interim financial statements are prepared on a quarterly basis ending on the Friday closest to the end of the calendar quarter, with the exception of the fourth quarter which always ends on December 31.

We design, develop, manufacture and sell precision photonic and motion control components and subsystems to Original Equipment Manufacturers (“OEMs”) in the medical equipment and advanced industrial technology markets. We specialize in collaborating with OEM customers to adapt our component and subsystem technologies to deliver highly differentiated performance in their applications. In March 2014, we acquired JADAK, a North Syracuse, New York-based provider of optical data collection and machine vision technologies to OEM medical device manufacturers, for $93.7 million in cash, net of working capital adjustments. The JADAK product line is reported as part of our Medical Technologies segment.

We operate in three reportable segments: Laser Products, Medical Technologies, and Precision Motion. The reportable segments and their principal activities consist of the following:

Our Medical Technologies segment designs, manufactures and markets a range of medical grade technologies, including visualization solutions, imaging informatics products, optical data collection and machine vision technologies, thermal printers, and light and color measurement instrumentation, to customers worldwide. The vast majority of the segment’s product offerings are sold to OEM customers. The segment sells these products both directly, utilizing a highly technical sales force, and indirectly, through resellers and distributors.

Our strategy is to drive sustainable, profitable growth through short-term and long-term initiatives, including:

On September 24, 2014, we received a payment of $5.4 million, the full remaining amount held in the escrow account established upon the closing of the acquisition of NDS in January 2013. The escrow recovery resulted from the Company’s claims for a breach of certain terms of the January 15, 2013 Securities Purchase Agreement for the acquisition of NDS. The escrow recovery was accounted for as a reduction to goodwill as the $5.4 million payment was clearly and directly related to the acquisition price. The escrow recovery resulted in a final adjusted NDS purchase price of $75.4 million.

On March 14, 2014, we completed the acquisition of JADAK, a North Syracuse, New York-based provider of optical data collection and machine vision technologies to OEM medical device manufacturers, for $93.7 million in cash, net of working capital adjustments. The addition of the JADAK technology platforms expands our portfolio of highly-differentiated enabling technologies. JADAK provides data collection and machine vision solutions to its customers, which primarily consist of OEM medical device manufacturers. JADAK’s products are based on technologies that include barcode components and scanners, machine vision cameras, RFID technology, magnetic stripe readers, portable platforms and associated software. JADAK’s products are highly engineered, application-specific components that are developed and manufactured to meet the extremely high performance and quality requirements of major medical OEMs. JADAK’s products are used in medical equipment to increase safety and reduce medical errors by verifying patient identity, validating the specified therapy or function, and enhancing the accuracy of the medical procedure.

On July 15, 2014, we completed the sale of certain assets and liabilities of our Scientific Lasers business operating under the Continuum brand name for $6.5 million in cash, net of working capital adjustments, and recognized a $0.3 million loss on sale during the three months ended September 26, 2014. The loss from discontinued operations of $5.1 million during the nine months ended September 26, 2014 includes a $3.0 million fair value write-down of the Scientific Lasers business to its estimated fair value less cost to sell. The Scientific Lasers purchase and sale agreement requires $1.5 million of the sales proceeds to be held in escrow that can be utilized as indemnification for certain representations and warranties claims against the Company until the expiration of the escrow arrangement in January 2016. The Company has recorded the $1.5 million escrow in other long term assets on the balance sheet.

Results of Operations for the Three and Nine Months Ended September 26, 2014 Compared with the Three and Nine Months Ended September 27, 2013

The following table sets forth our unaudited results of operations as a percentage of sales for the periods indicated:

	Three Months Ended						Nine Months Ended
	September 26, 2014			September 27, 2013			September 26, 2014			September 27, 2013
Sales		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		58.1			57.2			59.2			58.2
Gross profit		41.9			42.8			40.8			41.8
Operating expenses:
Research and development and engineering		8.2			7.6			7.8			7.7
Selling, general and administrative		22.7			23.8			23.1			24.3
Amortization of purchased intangible assets		3.0			2.2			2.8			2.4
Restructuring and acquisition related costs		0.8			1.9			0.7			2.0
Total operating expenses		34.7			35.5			34.4			36.4
Operating income from continuing operations		7.2			7.3			6.4			5.4
Interest income (expense), net		(1.5	)		(1.1	)		(1.4	)		(1.1	)
Foreign exchange transaction gains (losses), net		1.1			(2.2	)		0.4			(0.4	)
Other income (expense), net		0.7			0.7			0.7			0.5
Income from continuing operations before income taxes		7.5			4.7			6.1			4.4
Income tax provision		2.1			1.9			1.9			2.1
Income from continuing operations		5.4			2.8			4.2			2.3
Loss from discontinued operations, net of tax		(0.3	)		(0.2	)		(1.8	)		(0.7	)
Loss on disposal of discontinued operations, net of tax		(0.3	)		(0.4	)		(0.1	)		(0.3	)
Consolidated net income		4.8			2.2			2.3			1.3
Less: Net income (loss) attributable to noncontrolling interest		0.0			0.0			0.0			0.0
Net income attributable to GSI Group Inc.		4.8	%		2.2	%		2.3	%		1.3	%

Total sales for the three and nine months ended September 26, 2014 increased 18.5% and 15.3%, respectively, versus the prior year comparable periods. Our JADAK acquisition accounted for an 18.7% and 13.9% increase during the three and nine months ended September 26, 2014, respectively. In addition, foreign currency exchange rates favorably impacted our sales by 0.3% and 0.9% during the three and nine months ended September 26, 2014, respectively.

Excluding the impact of the JADAK acquisition and changes in foreign exchange rates, total sales decreased 0.5% for the three months ended September 26, 2014, versus the prior year comparable period, and increased 0.5% for the nine months ended September 26, 2014, versus the prior year comparable period. Our organic sales growth (decline) is summarized as follows:

The organic decline in our sales for the three months ended September 26, 2014 was attributable to a decline in Medical Technologies segment, partially offset by growth in our Laser Products and Precision Motion segments. The decrease in sales in our Medical Technologies segment was primarily driven by a decline in sales in our visualization solutions product line. The increase in sales of our Laser Products segment was primarily attributable to an increase in sales volume of our fiber lasers and CO₂ lasers. The growth in our Precision Motion segment was driven by increases in sales volume of optical encoders products, partially offset by a decline in our air bearing spindles product line.

The organic growth in our sales for the nine months ended September 26, 2014 was attributable to growth in our Laser Products and Precision Motion segments offset by a decline in Medical Technologies. The increase in sales in our Laser Products segment was attributable to an increase in sales volume across our product portfolio. The growth in our Precision Motion segment was driven by similar business dynamics affecting our sales for the three months ended September 26, 2014. These increases were partially offset by a decline in Medical Technologies related to our visualization solutions product line.

Operating income from continuing operations for the three months ended September 26, 2014 increased $1.0 million, or 17.6%, to $6.8 million from the prior year comparable period. This increase was primarily attributable to an increase in gross profit of $5.5 million as a result of higher sales, partially offset by a $4.5 million increase in operating expenses primarily attributable to the JADAK acquisition. Operating income from continuing operations for the nine months ended September 26, 2014 increased $4.7 million, or 37.3%, from the prior year comparable period. This increase was primarily due to an increase in gross profit and a decrease in restructuring and acquisition related costs, partially offset by an increase in selling, general and administrative (“SG&A”) and research and development and engineering (“R&D”) expenses as well as amortization of intangibles and acquisition fair value adjustments.

Diluted earnings per share (“Diluted EPS”) from continuing operations of $0.15 for the three months ended September 26, 2014 increased $0.08 from the prior year comparable period. This increase was primarily attributable to higher operating income from continuing operations and foreign currency gains in the current period versus foreign currency losses in the prior year comparable period, offset by an increase in interest expense as a result of higher average debt levels during 2014. Diluted EPS from continuing operations of $0.33 for the nine months ended September 26, 2014 increased by $0.18 from the prior year comparable period. Similar business dynamics affected Diluted EPS for the nine months ended September 26, 2014.

The following table sets forth sales by segment for the periods noted (dollars in thousands):

Laser Products segment sales for the three months ended September 26, 2014 increased by $1.1 million, or 2.4%, versus the prior year comparable period primarily due to growth in sales of our fiber lasers, driven by new customer wins, and an overall increase in sales of our CO₂ lasers products, driven by new product launches. During the quarter, both product lines were favorably impacted by an increase in capital spending in the advanced industrial technology market. These increases were partially offset by a decline in demand for our scanning technology products used in laser via-hole drilling applications.

Laser Products segment sales for the nine months ended September 26, 2014 increased by $8.2 million, or 6.6%, versus the prior year comparable period, due to growth in all product lines. The sales growth was primarily due to growth in sales of our fiber lasers, driven by new customer wins, and an overall increase in sales of our CO₂ lasers products, driven by new product launches.

Medical Technologies segment sales for the three months ended September 26, 2014 increased by $13.0 million, or 65.7%, versus the prior year comparable period. The JADAK acquisition accounted for $14.9 million of the increase in sales year over year, partially offset by a decline in sales in our visualization solutions products as a result of softness in medical equipment spending impacting our customer’s demand for our products and delays in new product introductions.

Medical Technologies segment sales for the nine months ended September 26, 2014 increased by $24.4 million, or 37.3%, versus the prior year comparable period. The JADAK acquisition accounted for $32.6 million of the increase in sales year over year, partially offset by a decline in sales in our visualization solutions products as a result of softness in medical equipment spending impacting our customer’s demand for our products, delays in new product introductions, and dual sourcing at an OEM customer that began in 2013.

Precision Motion segment sales for the three months ended September 26, 2014 increased by $0.7 million, or 4.8%, versus the prior year comparable period. This increase was driven by increased sales of our optical encoders products as a result of market share gains with a major OEM customer. This increase was partially offset by a decline in sales of our air bearing spindles products due to lower demand related to mechanical via-hole drilling of printed circuit boards.

Precision Motion segment sales for the nine months ended September 26, 2014 increased by $3.4 million, or 7.4%, versus the prior year comparable period. This increase was driven by increased sales of our optical encoders products as a result of new customer wins and market share gains with a major OEM customer. This increase was partially offset by a decline in sales of our air bearing spindles products due to lower demand related to mechanical via-hole drilling of printed circuit boards.

The following table sets forth the gross profit and gross profit margin for each of our reportable segments for the periods noted (dollars in thousands):

	Three Months Ended						Nine Months Ended
	September 26, 2014			September 27, 2013			September 26, 2014			September 27, 2013
Gross profit:
Laser Products	$	20,269		$	19,252		$	54,437		$	51,436
Medical Technologies		12,945			7,535			35,672			25,271
Precision Motion		6,776			7,429			21,141			21,487
Corporate		(307	)		(55	)		(811	)		(163	)
Total	$	39,683		$	34,161		$	110,439		$	98,031
Gross profit margin:
Laser Products		44.2	%		43.1	%		41.4	%		41.7	%
Medical Technologies		39.6	%		38.2	%		39.7	%		38.6	%
Precision Motion		41.9	%		48.2	%		42.8	%		46.7	%

Total		41.9	%		42.8	%		40.8	%		41.8	%

Gross profit and gross profit margin can be influenced by a number of factors, including product mix, pricing, volume, manufacturing efficiencies and utilization, costs for raw materials and outsourced manufacturing, headcount, inventory obsolescence and warranty expenses.

Laser Products segment gross profit for the three months ended September 26, 2014 increased $1.0 million, or 5.3%, versus the prior year comparable period due to Laser Products sales growth and an increase in gross profit margin. Laser Products segment gross profit margin was 44.2% for the three months ended September 26, 2014, versus a gross profit margin of 43.1% for the prior year comparable period. The 1.1 percentage point increase in gross profit margin was driven by gross profit margin improvements in our fiber lasers products and productivity improvements as a result of our manufacturing process improvement initiatives. In late 2013, we initiated a strategy and development program focused on producing cost competitive and flexible high-power fiber laser architecture to address an increasing demand from the market and our customers. This also included accelerating our new lower cost high-power fiber laser architecture development, focusing our development efforts, and reducing our overall organizational cost.

Laser Products segment gross profit for the nine months ended September 26, 2014 increased $3.0 million, or 5.8%, versus the prior year comparable period primarily due to Laser Products sales growth. Laser Products segment gross profit margin remained relatively flat year over year.

Medical Technologies segment gross profit for the three months ended September 26, 2014 increased $5.4 million, or 71.8%, versus the prior year comparable period. The increase was primarily attributable to the JADAK acquisition, which accounted for $6.4 million increase in gross profit year over year, partially offset by a decline in gross profit for our visualization solutions products due to lower sales. Medical Technologies segment gross profit margin was 39.6% for the three months ended September 26, 2014, versus a gross profit margin of 38.2% for the prior year comparable period. The 1.4 percentage point increase in gross profit margin was primarily attributable to the JADAK acquisition. Included in gross profit for the three months ended September 26, 2014 and September 27, 2013 was amortization of developed technologies of $0.9 million and $0.6 million, respectively.

Medical Technologies segment gross profit for the nine months ended September 26, 2014 increased $10.4 million, or 41.2%, versus the prior year comparable period. The increase was primarily attributable to the JADAK acquisition, which accounted for $13.4 million increase in gross profit year over year, partially offset by similar business dynamics affecting our gross profit for the three months ended September 26, 2014. Included in gross profit was amortization of developed technologies and amortization of inventory fair value step-ups of $2.8 million and $2.5 million for the nine months ended September 26, 2014 and September 27, 2013, respectively. Medical Technologies segment gross profit margin was 39.7% for the nine months ended September 26, 2014, versus a gross profit margin of 38.6% for the prior year comparable period. The increase in gross profit margin was primarily driven by similar business dynamics affecting our gross profit margin for the three months ended September 26, 2014.

Precision Motion segment gross profit for the three months ended September 26, 2014 decreased $0.7 million, or 8.8%, versus the prior year comparable period. The decrease in gross profit was due to a decline in sales volume of our air bearing spindles products partially offset by an increase in sales volume of our optical encoders products. Precision Motion segment gross profit margin was 41.9% for the three months ended September 26, 2014, versus a gross profit margin of 48.2% for the prior year comparable period. The decline in gross profit margin was due to an unfavorable product mix versus the prior year comparable period.

Precision Motion segment gross profit for the nine months ended September 26, 2014 decreased $0.3 million, or 1.6%, versus the prior year comparable period primarily due to similar business dynamics affecting our gross profit for the three months ended September 26, 2014. Precision Motion segment gross profit margin was 42.8% for the nine months ended September 26, 2014, versus a gross profit margin of 46.7% for the prior year comparable period. The decrease in gross profit margin was driven by similar business dynamics affecting our gross profit margin for the three months ended September 26, 2014.

The following table sets forth operating expenses for the periods noted (in thousands):

R&D expenses are primarily comprised of employee compensation related expenses and cost of materials for R&D projects. R&D expenses were $7.7 million, or 8.2% of sales, during the three months ended September 26, 2014, versus $6.0 million, or 7.6% of sales, during the prior year comparable period. R&D expenses increased in terms of total dollars primarily due to the acquisition of JADAK.

R&D expenses were $21.1 million, or 7.8% of sales, during the nine months ended September 26, 2014, versus $18.0 million, or 7.7% of sales, during the prior year comparable period. R&D expenses increased in terms of total dollars due to the acquisition of JADAK.

SG&A expenses include costs for sales and marketing, sales administration, finance, human resources, legal, information systems, and executive management functions. SG&A expenses were $21.5 million, or 22.7% of sales, during the three months ended September 26, 2014, versus $19.0 million, or 23.8% of sales, during the prior year comparable period. SG&A expenses increased in terms of total dollars primarily due to the acquisition of JADAK.

SG&A expenses were $62.5 million, or 23.1% of sales, during the nine months ended September 26, 2014, versus $57.1 million, or 24.3% of sales, during the prior year comparable period. SG&A expenses increased in terms of total dollars primarily due to the acquisition of JADAK.

Amortization of purchased intangible assets, excluding the amortization for developed technologies included in cost of sales, was $2.8 million, or 3.0% of sales, during the three months ended September 26, 2014, versus $1.8 million, or 2.2% of sales, during the prior year comparable period. The increase, in terms of total dollars and as a percentage of sales, was related to the increase in amortization of acquired intangible assets from the JADAK acquisition.

Amortization of purchased intangible assets, excluding the amortization for developed technologies that is included in cost of sales, was $7.5 million, or 2.8% of sales, during the nine months ended September 26, 2014, versus $5.6 million, or 2.4% of sales,

during the prior year comparable period. The increase, in terms of total dollars and as a percentage of sales, was related to the amortization of acquired intangible assets from the JADAK acquisition.

We recorded restructuring and acquisition related costs of $0.8 million during the three months ended September 26, 2014, versus $1.6 million during the prior year comparable period. During the three months ended September 26, 2014, we recognized acquisition related costs of $0.6 million, which primarily related to expenses recognized under earn-out agreements in connection with the JADAK acquisition and $0.2 million of restructuring costs from facilities previously exited. During the nine months ended September 26, 2014, we recorded restructuring and acquisition related costs of $1.9 million, versus $4.7 million during the prior year comparable period. The decrease in restructuring and acquisition related costs during the three and nine month periods ended September 26, 2014 versus the prior year comparable periods is mainly due to the decrease in costs related to the 2011 and 2013 restructuring plans. Acquisition related costs for the nine months ended September 26, 2014 and September 27, 2013 were $1.9 million and $1.2 million, respectively.

The following table sets forth operating income from continuing operations by segment for the periods noted (in thousands):

	Three Months Ended						Nine Months Ended
	September 26, 2014			September 27, 2013			September 26, 2014			September 27, 2013
Operating Income from Continuing Operations
Laser Products	$	9,857		$	7,734		$	23,828		$	17,868
Medical Technologies		(1,115	)		(469	)		(1,194	)		1,375
Precision Motion		2,796			3,223			9,525			9,657
Corporate, shared services and unallocated		(4,716	)		(4,689	)		(14,789	)		(16,249	)
Total	$	6,822		$	5,799		$	17,370		$	12,651

Laser Products operating income from continuing operations for the three months ended September 26, 2014 increased by $2.1 million, or 27.5%, versus the prior year comparable period. The increase in operating income from continuing operations was due to an increase in gross profit, lower restructuring and acquisition related costs and, to a lesser extent, a decrease in operating expenses. Restructuring costs for the three months ended September 26, 2014 decreased by $0.7 million from the prior year comparable period.

Laser Products operating income from continuing operations for the nine months ended September 26, 2014 increased by $6.0 million, or 33.4%, primarily due to an increase in gross profit, lower restructuring and acquisition related costs and, to a lesser extent, a decrease in operating expenses. Restructuring costs for the nine months ended September 26, 2014 decreased by $1.9 million from the prior year comparable period.

Medical Technologies operating income from continuing operations for the three months ended September 26, 2014 decreased by $0.6 million, or 137.7%, versus the prior year comparable period. The decrease was primarily attributable to an increase in amortization of intangible assets of $1.3 million as result of the JADAK acquisition and a decline in visualization solutions revenue, partially offset by operating income from continuing operations from the JADAK acquisition.

Medical Technologies operating income from continuing operations for the nine months ended September 26, 2014 decreased by $2.6 million, or 186.8%, versus the prior year comparable period. The decrease was attributable to an increase in amortization of intangibles and amortization of our inventory fair value step-ups of $2.0 million and a decline in visualization solutions revenue, partially offset by an increase in operating income from continuing operations from the JADAK acquisition.

Precision Motion operating income from continuing operations for the three months ended September 26, 2014 decreased by $0.4 million, or 13.2%, versus the prior year comparable period. The decrease was primarily due to a decline in gross profit, offset by lower restructuring costs.

Precision Motion operating income from continuing operations for the nine months ended September 26, 2014 decreased by $0.1 million, or 1.4%, primarily due to a decline in gross profit of the air bearing spindles products.

Corporate, shared services and unallocated costs primarily represent costs of corporate functions that are not allocated to the operating segments, including certain restructuring and most acquisition related costs. These costs for the three months ended September 26, 2014 remained relatively consistent to the prior year comparable period. Corporate, shared services and unallocated costs for the nine months ended September 26, 2014 decreased versus the prior year comparable periods due to lower restructuring costs related to the 2011 and 2013 restructuring plans and savings from prior restructurings. The Company recorded restructuring and acquisition related costs of $0.2 million and $1.0 million during the three and nine months ended September 26, 2014, respectively, versus $0.3 million and $1.7 million in the prior year comparable periods.

The following table sets forth other income and expense items for the periods noted (dollars in thousands):

The increase in net interest expense in the three and nine months ended September 26, 2014 versus the prior year comparable periods was the result of higher average debt levels and higher average interest rates during 2014. The weighted average interest rate on our Senior Credit Facilities was 3.23% and 2.93% during the three months ended September 26, 2014 and September 27, 2013, respectively, and 3.22% and 2.84% during the nine months ended September 26, 2014 and September 27, 2013, respectively. Included in interest income (expense), net was non-cash interest expense of approximately $0.2 million and $0.7 million related to amortization of deferred financing costs on our debt during the three and nine month periods ended September 26, 2014 and September 27, 2013, respectively.

Foreign exchange transaction gains (losses), net, were $1.0 million net gains for the three months ended September 26, 2014, versus ($1.7) million net losses for the prior year comparable period due to changes in the U.S. Dollar against the Euro, British Pound and Japanese Yen.

Foreign exchange transaction gains (losses), net, were $1.0 million net gains for the nine months ended September 26, 2014, versus ($1.0) million net losses for the prior year comparable period due to changes in the U.S. Dollar against the Euro, Japanese Yen, and British Pound.

Other income (expense), net, was $0.7 million and $1.7 million during the three and nine months ended September 26, 2014, respectively, compared to $0.5 million and $1.2 million during the three and nine months ended September 27, 2013, respectively. Other income (expense), increased for the three and nine months ended September 26, 2014 versus the prior year comparable periods as a result of higher earnings from our equity-method investment in Laser Quantum.

The effective tax rate for the three months ended September 26, 2014 was 28.2%, versus 40.6% for the prior year comparable period. The effective tax rates for the three months ended September 26, 2014 and September 27, 2013 differ from the Canadian statutory rate of 27.0%, primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a

full valuation allowance, and the impact of discrete items. The discrete items in the quarter are related to additional R&D tax credits identified as a result of a comprehensive study.

The effective tax rate for the nine months ended September 26, 2014 was 30.6%, versus 48.4% for the prior year comparable period. The effective tax rates for the nine months ended September 26, 2014 and September 27, 2013 differ from the Canadian statutory rate of 27.0%, respectively, primarily due to the mix of income earned in jurisdictions with varying tax rates, losses in jurisdictions with a full valuation allowance, and the impact of discrete items.

The Company recognized a net tax expense associated with additional uncertain tax positions of $0.2 million during the three months ended September 26, 2014 and a net tax benefit mainly associated with uncertain tax positions of $1.1 million due to the expiration of the statute of limitations during the nine months ended September 26, 2014.

Loss from discontinued operations, net of tax, was $0.3 million and $4.8 million during the three and nine months ended September 26, 2014, compared to loss from discontinued operations, net of tax, of $0.2 million and $1.6 million during the three and nine months ended September 27, 2013. The increase in the loss from discontinued operations for the three months ended September 26, 2014 versus the prior year comparable period was primarily due to an impairment charge of $0.5 million in connection with our joint venture investment in Excel Laser Technology Private Limited, which is part of our Scientific Lasers business. The increase in the loss from discontinued operations, net of tax, for the nine months ended September 26, 2014 was primarily due to the sale of the Scientific Lasers business, which resulted in a $3.0 million fair value write-down of the Scientific Lasers business and the fair value write-down of $0.5 million in connection with our joint venture investment in Excel Laser Technology Private Limited.

In July 2014, we completed the sale of the Scientific Lasers business. As a result, we recorded a loss on sale, net of tax, of $0.3 million during the three months ended September 26, 2014.

We assess our liquidity in terms of our ability to generate cash to fund our operating, investing, and financing activities. Our primary ongoing cash requirements are funding operations, capital expenditures, investments in businesses, and repayment of our debt and related interest expense. Our primary sources of liquidity are cash flows from operations and borrowings under our revolving credit facility. We believe our future operating cash flows will be sufficient to meet our future operating and investing cash needs for the foreseeable future, including at least the next 12 months. The availability of borrowings under our revolving credit facility provides an additional potential source of liquidity should it be required. In addition, we may seek to raise additional capital, which could be in the form of bonds, convertible debt or equity, to fund business development activities or other future investing cash requirements, subject to approval by the lenders in the Amended and Restated Credit Agreement.

The sources of our liquidity are subject to all of the risks of our business and could be adversely affected by, among other factors, a decrease in demand for our products, our ability to integrate current and future acquisitions, deterioration in certain financial ratios, and market changes in general. See “Risks Relating to Our Common Shares and Our Capital Structure” included in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Our ability to make payments on our indebtedness and to fund our operations may be dependent upon the earnings and the distribution of funds from our subsidiaries. Local laws and regulations and/or the terms of our indebtedness restrict certain of our subsidiaries from paying dividends and transferring assets to us. We cannot assure you that applicable laws and regulations and/or the terms of our indebtedness will permit our subsidiaries to provide us with sufficient dividends, distributions or loans when necessary.

As of September 26, 2014, $19.3 million of our $53.5 million cash and cash equivalents was held by our subsidiaries outside of Canada and the United States. Generally, our intent is to use cash held in these foreign subsidiaries to fund our local operations or acquisitions. However, in certain instances, we have identified excess cash for which we may repatriate and we have established deferred tax liabilities for the expected tax cost. Additionally, we may use intercompany loans to address short-term cash flow needs for various subsidiaries.

laws. Repurchases may be made under certain SEC regulations, which would permit common stock to be purchased when the Company would otherwise be prohibited from doing so under insider trading laws. The share repurchase plan does not obligate the Company to acquire any particular amount of common stock. No time limit was set for the completion of the share repurchase program, and the program may be suspended or discontinued at any time. The Company expects to fund share repurchases through cash on hand and future cash flow from operations. As of December 31, 2013, the Company repurchased 50 thousand shares of its common stock for an aggregate amount of $0.5 million on the open market for a weighted average price of $10.49 per share. There have been no share repurchases to date in 2014.

In December 2012, we entered into an amended and restated senior secured credit agreement (the “Amended and Restated Credit Agreement”), consisting of a $50.0 million, 5-year term loan facility and a $75.0 million, 5-year revolving credit facility (collectively, the “Senior Credit Facilities”). The Senior Credit Facilities mature in December 2017. On February 10, 2014, we entered into a fourth amendment to the Amended and Restated Credit Agreement (the “Fourth Amendment”). The Fourth Amendment increased the revolving credit facility commitment under the Amended and Restated Credit Agreement by $100 million from $75 million to $175 million and reset the accordion feature to $100 million for future expansion. Additionally, the Fourth Amendment increased the maximum permitted consolidated leverage ratio financial covenant from 2.75 to 3.00.

As of September 26, 2014, we had outstanding term loans of $36.9 million and revolving loans of $85.0 million outstanding under the Senior Credit Facilities.

The Amended and Restated Credit Agreement contains various covenants that we believe are usual and customary for this type of agreement, including a maximum allowed leverage ratio, and a minimum required fixed charge coverage ratio (as defined in the Amended and Restated Credit Agreement). The following table summarizes these financial covenant requirements and our compliance as of September 26, 2014:

The following table summarizes our cash and cash equivalent balances, cash flows from continuing operations and unused and available funds under our revolving credit facility for the periods indicated (dollars in thousands):

Cash provided by operating activities of continuing operations was $34.4 million for the nine months ended September 26, 2014, compared to $41.3 million for the prior year comparable period. Income from continuing operations for the nine months ended September 26, 2014 increased from the prior year comparable period while changes in operating assets and liabilities decreased cash for the nine months ended September 26, 2014 by $2.4 million. This compares to a $12.9 million increase in cash provided by changes in operating assets and liabilities for the nine months ended September 27, 2013, primarily due to a $12.5 million tax refund received as a result of settlement with the IRS.

Cash used in operating activities of discontinued operations was $0.8 million for the nine months ended September 26, 2014, compared to cash used in operating activities of $6.9 million from the prior year comparable period. The decrease in cash used in

operating activities of discontinued operations was primarily the result of the divestiture of the Semiconductor Systems business during the prior year.

Net cash used in investing activities of our continuing operations was $92.0 million during the nine months ended September 26, 2014, compared to $85.4 million during the nine months ended September 27, 2013. Cash used in investing activities for the nine months ended September 26, 2014 was primarily due to cash consideration paid for the JADAK acquisition in March 2014 and $3.8 million in capital expenditures, offset by proceeds of $5.4 million related to the recovery of an escrow claim for the acquisition of NDS. Cash outflows from investing activities of continuing operations during the nine months ended September 27, 2013 were primarily related to cash consideration paid for the NDS acquisition in January 2013 and $3.0 million in capital expenditures.

Cash provided by investing activities of discontinued operations was $4.3 million for the nine months ended September 26, 2014, compared to proceeds of $12.4 million from the prior year comparable period. Cash provided by investing activities of discontinued operations for the nine months ended September 26, 2014 was primarily related to $5.3 million of net proceeds from the sale of the Scientific Lasers business, offset by capital expenditures of $0.9 million. Cash provided by investing activities of discontinued operations for the nine months ended September 27, 2013 was primarily due to $8.2 million net proceeds from the sale of the Semiconductor Systems business and $4.6 million proceeds from the sale of our East Setauket, New York facility which was part of our Scientific Lasers business.

Cash provided by financing activities of continuing operations was $47.6 million during the nine months ended September 26, 2014, consisting of $77.0 million of borrowings under our revolving credit facility to fund the JADAK acquisition, offset by $5.6 million of contractual term loan payments, $21.0 million of optional repayments of borrowings under our revolving credit facility and $0.7 million fees paid in connection with the Fourth Amendment. The Company also made payroll tax payments on stock-based awards of $1.6 million and capital lease payments of $0.9 million.

Cash provided by financing activities of continuing operations was $26.8 million during the nine months ended September 27, 2013, consisting of $60.0 million of borrowings under our revolving credit facility to fund the NDS acquisition, offset by contractual repayments on our term loan of $5.6 million, optional repayments of borrowings under our revolving credit facility of $26.0 million and $0.1 million bank fees. The Company also made payroll tax payments on stock-based awards of $0.8 million and capital lease payments of $0.6 million in the nine months ended September 27, 2013.

Our contractual obligations primarily consist of the principal and interest associated with our debt, operating and capital leases, purchase commitments and pension obligations. Such contractual obligations are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Excluding the outstanding lease commitment assumed by the buyer of the Scientific Lasers business and leases and purchase commitments in the ordinary course of business acquired as a result of the JADAK acquisition and the $70.0 million drawdown on our Senior Credit Facilities to fund the JADAK acquisition, through September 26, 2014, we have not entered into any material new or modified contractual obligations since the end of the fiscal year ended December 31, 2013. The following table summarizes contractual obligations at September 26, 2014 related to JADAK (in thousands):

The Company has an equity method investment in a privately held company located in the United Kingdom, Laser Quantum Ltd. Group (“Laser Quantum”). The Company has an ownership interest of approximately 41% in the Laser Quantum business. We continue to recognize our share of the earnings of this entity under the equity method.

Through September 26, 2014, we have not entered into any other off-balance sheet arrangements or material transactions with any unconsolidated entities or other persons.

The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our consolidated financial statements presented in this report are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to Consolidated Financial Statements, each included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have been no material changes to our critical accounting policies through September 26, 2014 from those discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

Our primary market risk exposures are foreign currency exchange rate fluctuation and interest rate sensitivity. During the nine months ended September 26, 2014, there have been no material changes to the information included under Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013.

As required by Rule 13a-15(b) under the Exchange Act, our management carried out an evaluation, with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of September 26, 2014, the end of the period covered by this report. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 26, 2014.

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter ended September 26, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

The Company’s risk factors are described in Part I, Item 1A, “Risk Factors”, of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2013. There have been no material changes in the risks affecting the Company since the filing of such Annual Report on Form 10-K.

See the Company’s SEC filings on Edgar at: http://www.sec.gov/ for all Exhibits.

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing
Date

Filed
Herewith

3.1

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999.

S-3

333-180098

3.1

03/14/12

3.2

Articles of Amendment of the Registrant, dated May 26, 2005.

S-3

333-180098

3.1

03/14/12

3.3

By-Laws of the Registrant, as amended

10-Q

000-25705

3.2

04/13/10

3.4

Articles of Reorganization of the Registrant, dated July 23, 2010.

8-K

000-25705

3.1

07/23/10

3.5

Articles of Amendment of the Registrant, dated December 29, 2010.

8-K

000-25705

3.1

12/29/10

31.1

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Schema Document

101.CAL

XBRL Calculation Linkbase Document.

101.DEF

XBRL Definition Linkbase Document.

101.LAB

XBRL Labels Linkbase Document.

101.PRE

XBRL Presentation Linkbase Document.

Attached as Exhibit 101 to this report are the following formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets at September 26, 2014 and December 31, 2013, (ii) Consolidated Statements of Operations for the three and nine months ended September 26, 2014 and September 27, 2013, (iii) Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 26, 2014 and September 27, 2013, (iv) Consolidated Statements of Cash Flows for the nine months ended September 26, 2014 and September 27, 2013, and (v) Notes to Consolidated Financial Statements.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Incorporated by Reference

Exhibit

Number

Exhibit Description

Form

File No.

Exhibit

Filing

Date

Filed

Herewith

3.1

Certificate and Articles of Continuance of the Registrant, dated March 22, 1999.

S-3

333-180098

3.1

03/14/12

3.2

Articles of Amendment of the Registrant, dated May 26, 2005.

S-3

333-180098

3.1

03/14/12

3.3

By-Laws of the Registrant, as amended

10-Q

000-25705

3.2

04/13/10

3.4

Articles of Reorganization of the Registrant, dated July 23, 2010.

8-K

000-25705

3.1

07/23/10

3.5

Articles of Amendment of the Registrant, dated December 29, 2010.

8-K

000-25705

3.1

12/29/10

31.1

Chief Executive Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2

Chief Financial Officer Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2

Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Schema Document

101.CAL

XBRL Calculation Linkbase Document.

101.DEF

XBRL Definition Linkbase Document.

101.LAB

XBRL Labels Linkbase Document.

101.PRE

XBRL Presentation Linkbase Document.

New Brunswick, Canada		98-0110412
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

125 Middlesex Turnpike Bedford, Massachusetts, USA		01730
(Address of principal executive offices)		(Zip Code)

Large accelerated filer	¨	Accelerated filer	x

Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨

Item No.		Page No.

PART I — FINANCIAL INFORMATION		1

ITEM 1.	FINANCIAL STATEMENTS	1

	CONSOLIDATED BALANCE SHEETS (unaudited)	1

	CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)	2

	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited)	3

	CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)	4

	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)	5

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	20

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	32

ITEM 4.	CONTROLS AND PROCEDURES	32

PART II — OTHER INFORMATION		33

ITEM 1.	LEGAL PROCEEDINGS	33

ITEM 1A.	RISK FACTORS	33

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	33

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	33

ITEM 4.	MINE SAFETY DISCLOSURES	33

ITEM 5.	OTHER INFORMATION	33

ITEM 6.	EXHIBITS	34

SIGNATURES		35

EXHIBIT INDEX		36

	Purchase Price
	Allocation
Cash	$	1,140
Accounts receivable		7,907
Inventory		6,791
Property and equipment		904
Intangible assets		40,250
Goodwill		45,045
Other assets		1,979
Total assets acquired		104,016

Accounts payable		3,057
Other liabilities		2,074
Deferred tax liabilities		4,089
Total liabilities assumed		9,220
Total purchase price		94,796
Less cash acquired		(1,140	)
Total purchase price, net of cash acquired	$	93,656

			Weighted Average
	Estimated Fair		Amortization
	Value		Period
Customer relationships	$	23,570	20 years
Developed technology		10,910	10 years
Trademarks and trade names		2,130	10 years
Backlog		1,810	1 year
Non-compete covenant		1,830	5 years
Total	$	40,250

	Three Months		Nine Months		Cumulative
	Ended		Ended		Costs
	September 26,		September 26,		September 26,
	2014		2014		2014
Acquisition-related costs	$	—	$	668	$	975

	Total accumulated
	other			Foreign currency
	comprehensive			translation			Pension
	income (loss)			adjustments			liability
Balance at December 31, 2013	$	(6,342	)	$	1,353		$	(7,695	)
Other comprehensive income (loss)		(2,783	)		(2,902	)		119
Amounts reclassified from other comprehensive income (loss) ⁽¹⁾		330			—			330
Balance at September 26, 2014	$	(8,795	)	$	(1,549	)	$	(7,246	)

Balance at beginning of the period	$	71,156
Goodwill acquired from the JADAK acquisition		45,045
Recovery of escrow from the NDS acquisition		(5,418	)
Balance at end of period	$	110,783

	Reportable Segment
	Laser Products			Medical Technologies			Precision Motion			Total
Goodwill	$	132,954		$	83,192		$	26,291		$	242,437
Accumulated impairment of goodwill		(102,461	)		(12,147	)		(17,046	)		(131,654	)
Total	$	30,493		$	71,045		$	9,245		$	110,783

Year Ending December 31,	Cost of Sales		Operating Expenses		Total
2014 (remainder of year)	$	1,614	$	2,800	$	4,414
2015		4,787		9,454		14,241
2016		3,376		9,222		12,598
2017		2,883		8,259		11,142
2018		1,350		7,378		8,728
Thereafter		4,543		24,850		29,393
Total	$	18,553	$	61,963	$	80,516

	September 26, 2014		December 31, 2013
Raw materials	$	38,281	$	34,749
Work-in-process		11,069		9,744
Finished goods		11,403		10,682
Demo and consigned inventory		2,062		3,115
Total inventories	$	62,815	$	58,290

	September 26, 2014		December 31, 2013
Accrued compensation and benefits	$	7,592	$	8,624
Accrued warranty		3,223		3,315
Customer deposits		524		551
Other		7,739		9,798
Total	$	19,078	$	22,288

	September 26, 2014		December 31, 2013
Senior Credit Facilities – term loan	$	36,875	$	42,500
Senior Credit Facilities – revolving credit facility		85,000		29,000
Total Senior Credit Facilities	$	121,875	$	71,500

	Restricted Stock Units (In thousands)			Weighted Average Grant Date Fair Value
Unvested at December 31, 2013		809		$	10.20
Granted		316		$	12.31
Vested		(346	)	$	10.83
Forfeited		(5	)	$	10.25
Unvested at September 26, 2014		774		$	10.78
Expected to vest as of September 26, 2014		755

	Total			Severance			Facility			Other
Balance at December 31, 2013	$	1,272		$	585		$	648		$	39
Restructuring charges		73			(79	)		68			84
Cash payments		(765	)		(441	)		(249	)		(75	)
Non-cash write-offs and other adjustments		(374	)		—			(374	)		—
Balance at September 26, 2014	$	206		$	65		$	93		$	48

Year Ending December 31,	Operating Lease		Capital Lease⁽¹⁾
2014 (remainder of year)	$	17	$	201
2015		69		803
2016		—		803
2017		—		831
2018		—		860
Thereafter		—		9,928
Total minimum lease payments	$	86	$	13,426

	Three Months Ended September 26, 2014 Percentage Change			Nine Months Ended September 26, 2014 Percentage Change
Reported growth		18.5	%		15.3	%
Less: Change attributable to JADAK acquisition		18.7	%		13.9	%
Less: Change due to foreign currency		0.3	%		0.9	%
Organic growth (decline)		(0.5	)%		0.5	%

	Requirement		Actual
Maximum consolidated leverage ratio		3.00		2.07
Minimum consolidated fixed charge coverage ratio		1.50		4.11

Contractual Obligations	Total		2014 (remainder of year)		2015-2016		2017-2018		Thereafter
Capital leases	$	13,426	$	201	$	1,606	$	1,691	$	9,928
Operating leases		86		17		69		—		—
Purchase commitments ⁽¹⁾		5,072		3,312		1,760		—		—
Total	$	18,584	$	3,530	$	3,435	$	1,691	$	9,928

Name	Title	Date

/s/ John A. Roush	Director, Chief Executive Officer	November 5, 2014
John A. Roush

/s/ Robert J. Buckley	Chief Financial Officer	November 5, 2014
Robert J. Buckley